More than £17 billion was wiped from AstraZeneca's market value after reports emerged of preliminary discussions to acquire US drugmaker Bristol Myers Squibb. The proposed $400 billion transaction would create the world's fourth-largest pharmaceutical company, but investors questioned both the strategic rationale and the financial structure of such a landmark deal.